Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FC505
- Development stage
- Preclinical
- Lead developer
- FutureChem
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-FC505 is a fluorine-18 ([18F]) labeled small molecule radiopharmaceutical under development by FutureChem Pharma as a diagnostic imaging agent. It is specifically designed for Positron Emission Tomography (PET) to detect and evaluate atherosclerotic plaques. The tracer is intended to identify vulnerable plaques that are at high risk of rupture, potentially aiding in the prevention of myocardial infarction and stroke. Currently in the preclinical stage, 18F-FC505 leverages the high sensitivity of PET imaging to provide detailed information on plaque composition or inflammatory activity within the arterial wall.
- Other names
- [18F]FC505
Beyond the preview
Go deeper on 18F-FC505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FC505.